Barzolvolimab Fails Phase 2 Atopic Dermatitis Trial; Celldex Drops the Indication
CLDX sits 21% above its 52-week low of $22.33.
Summary
Celldex's Phase 2 study of barzolvolimab in moderate-to-severe atopic dermatitis missed its primary endpoint — percent change in weekly PP-NRS at Week 16 was -29.2% for the 300mg dose versus -19.5% for placebo (p=0.187) — and key secondary endpoints (EASI, IGA 0/1) did not meaningfully separate from placebo. The company is discontinuing development in AD, saying the data suggest mast cells are not a primary driver of the disease. This is a setback for the pipeline's breadth but not for the core thesis: the September 2026 Phase 3 EMBARQ-CSU1/CSU2 readout hit primary and all key secondary endpoints, and Celldex still plans a 2027 BLA submission in chronic spontaneous urticaria with Phase 3 work ongoing in cold urticaria and symptomatic dermographism. The AD miss removes an optional expansion indication rather than the lead asset's value driver, though it trims the bull case for label expansion. Cash of $650.3M as of the Q3 report and a fresh $297M shelf give runway, but the wider Q3 loss of $75.6M shows spending is climbing ahead of the BLA.
At the time of this announcement, CLDX was trading at $27.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $22.33 to $45.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.